These therapies target the PDL1 ligand on tumors or the PD1 receptor on T cells, and this leads to activation of effector T cells and prevents tumor immune escape.[35] Therefore, it is necessary to identify new biomarkers that provide better predictions of clinical response and can potentially be used as immunotherapy targets for more effective combination therapies that overcome immune resistance. The gene discussed is CD274; the disease is neoplasm.